stockrowOrganon & Co.
OGNHealthcare Drug Manufacturers General
Organon & Co.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, down 2.92% from fiscal 2024.
- Revenue
- −1.75%
- EPS
- +1.64%
- Free cash flow
- +118.8%
- Total debt
- −3.10%
Quarter to September 2026, against a year earlier
Follow OGN
Alert me
Organon & Co. (OGN) Return on assets
Organon & Co.'s return on assets over the twelve months to 30 September 2026 was 1.58%, up 0.1 percentage points from fiscal 2025 (1.44%). Over the past ten years it has ranged from 0.00% (fiscal 2018) to 61.0% (fiscal 2019); the current reading is higher than 33% of that period. That is below the Drug Manufacturers General industry median of 2.28% and above the Healthcare sector median of −29.5%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 1.44% | (5.43) |
| FY2024 | 6.87% | (2.02) |
| FY2023 | 8.89% | 0.41 |
| FY2022 | 8.48% | (4.52) |
| FY2021 | 13.0% | (7.91) |
| FY2020 | 20.9% | (40.11) |
| FY2019 | 61.0% | 61.02 |
| FY2018 | 0.00% | 0.00 |
| FY2017 | 0.00% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| NVO Novo Nordisk A/S compare | 20.5% |
| BMY Bristol Myers Squibb Company compare | 9.96% |
| GSK GSK PLC Sponsored ADR compare | 6.53% |
| SNY Sanofi compare | 3.24% |
| GRFS Grifols, S.A. compare | 2.28% |
| PFE Pfizer Inc. compare | 1.95% |
| OGN Organon & Co. | 1.58% |
| BIIB Biogen Inc. compare | 1.13% |
| AMRN Amarin Corporation PLC compare | −2.96% |
| Drug Manufacturers General industry median | 2.28% |
| Healthcare sector median | −29.5% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on OGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement